阿哌沙班与利伐沙班在静脉血栓栓塞症患者中预防复发性静脉血栓栓塞和不良出血事件的有效性和安全性:一项回顾性人群队列分析
该研究基于美国Truven Health MarketScan商业与Medicare补充理赔数据库,纳入2014年1月1日至2016年12月31日新诊断静脉血栓栓塞症且新使用阿哌沙班或利伐沙班的成人患者,经倾向评分匹配后分析15254例。阿哌沙班组复发性静脉血栓栓塞和大出血发生率均低于利伐沙班组,多变量Cox回归显示阿哌沙班与两者风险降低相关。作者认为阿哌沙班似乎比利伐沙班更有效。
要点
- 倾向评分匹配后纳入15254例,阿哌沙班组3091例、利伐沙班组12163例。
- 复发性静脉血栓栓塞粗发生率阿哌沙班组每100人年3例 vs 利伐沙班组每100人年7例。
- 大出血粗发生率阿哌沙班组每100人年3例 vs 利伐沙班组每100人年6例。
核心结论
- 与利伐沙班相比,阿哌沙班的使用与复发性静脉血栓栓塞风险降低相关(HR 0.37 [95% CI 0.24-0.55];p<0.0001)。
- 与利伐沙班相比,阿哌沙班的使用与大出血事件风险降低相关(HR 0.54 [95% CI 0.37-0.82];p=0.0031)。
- 作者认为,基于本研究发现,阿哌沙班在预防复发性静脉血栓栓塞和大出血事件方面似乎比利伐沙班更有效。
研究设计与样本
- 研究类型为回顾性队列分析,数据来自美国Truven Health MarketScan商业与Medicare补充理赔数据库。
- 纳入2014年1月1日至2016年12月31日新诊断静脉血栓栓塞症(深静脉血栓或肺栓塞)且新使用阿哌沙班或利伐沙班的成人患者。
- 排除诊断后30天内未启动研究药物者、医疗与药房福利连续入组不足12个月者、基线期使用其他抗凝药者。
- 经倾向评分匹配后,队列共纳入15254例患者(阿哌沙班使用者3091例,利伐沙班使用者12163例)。
- 采用倾向评分匹配后的Cox比例风险模型计算风险比(HR)和95% CI。
主要发现
- 复发性静脉血栓栓塞的粗发生率为阿哌沙班组每100人年3例 vs 利伐沙班组每100人年7例。
- 大出血的发生率为阿哌沙班组每100人年3例 vs 利伐沙班组每100人年6例。
- 多变量Cox回归模型中,与利伐沙班相比,阿哌沙班的使用与复发性静脉血栓栓塞风险降低相关(HR 0.37 [95% CI 0.24-0.55];p<0.0001)。
- 多变量Cox回归模型中,与利伐沙班相比,阿哌沙班的使用与大出血事件风险降低相关(HR 0.54 [95% CI 0.37-0.82];p=0.0031)。
临床怎么用
- 作者认为,本研究数据可能给临床医生一些保证,即阿哌沙班可作为治疗静脉血栓栓塞症患者的有效且安全的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being increasingly used in routine clinical practice because of their fixed dosing and favourable pharmacological profiles. Differences in the risk of recurrent venous thromboembolism and major bleeding events between the two drugs are currently unknown. We aimed to compare the effectiveness and safety of apixaban and rivaroxaban in prevention of recurrent venous thromboembolism and major bleeding events in patients with venous thromboembolism. METHODS: We did a retrospective cohort analysis of data from the Truven Health MarketScan commercial and Medicare Supplement claims databases in the USA. We analysed data for adult patients with newly diagnosed venous thromboembolism (deep vein thrombosis or pulmonary embolism) who were new users of apixaban or rivaroxaban between Jan 1, 2014, and Dec 31, 2016. Patients who did not initiate the study drugs within 30 days of their diagnosis, those without 12 months of continuous enrolment in medical and pharmacy benefits, and those who used other anticoagulants during the baseline period were excluded. The primary effectiveness outcome was the incidence of recurrent venous thromboembolism and the primary safety outcome was the incidence of major bleeding events. Cox-proportional hazard models after propensity score matching were used to calculate the hazard ratio (HR) and 95% CI. FINDINGS: After propensity score matching, 15 254 patients were included in the cohort (3091 apixaban users and 12 163 rivaroxaban users). The crude incidence of recurrent venous thromboembolism was three per 100 person-years in the apixaban group and seven per 100 person-years in the rivaroxaban group. The incidence of major bleeding was three per 100 person-years in the apixaban group and six per 100 person-years in the rivaroxaban group. In multivariable Cox regression models, the use of apixaban compared with rivaroxaban was associated with decreased risk of recurrent venous thromboembolism (HR 0·37 [95% CI 0·24-0·55]; p<0·0001) and major bleeding events (0·54 [0·37-0·82]; p=0·0031). INTERPRETATION: Based on our findings, apixaban seems to be more effective than rivaroxaban in preventing the development of recurrent venous thromboembolism and major bleeding events. Our data might give some assurance to clinicians that apixaban can be an effective and safe therapeutic option for treatment of patients with venous thromboembolism. FUNDING: None.
引用
- Dawwas GK, Brown J, Dietrich E, et al. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol. 2018. PMID: 30558988. doi:10.1016/S2352-3026(18)30191-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。